Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Sanofi","sponsor":"LTL Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LTL Pharma to Take Over Sanofi\u2019s Diregura in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D\u00ae 24 Hr in the U.S. Market","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for MolPort-001-684-474

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Allegra-D (fexofenadine) is an over-the-counter oral antihistamine and nasal decongestant for the temporary relief of nasal and sinus congestion due to colds or allergies.

            Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Allegra-D

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2022

            Details:

            LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).

            Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine

            Therapeutic Area: Immunology Product Name: Diregura

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: LTL Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 04, 2020

            Sanofi Company Banner

            Iran Expo

            Not Confirmed

            envelop Contact Supplier
            Post Enquiry
            POST ENQUIRY